Search

everythinglearnresearchcommunity

for

Search:↓

Androgen receptor overexpression can increase prostate cancer cell growth even without hormones.

Wedelolactone selectively kills prostate cancer cells without harming normal cells.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

Precise objectives can improve student achievement in health education.

Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.

Finasteride and dutasteride may lower melanoma risk, with teenage acne possibly indicating higher risk.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

Green tea extract and cycling hormone treatments may help treat advanced prostate cancer.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

Hair loss gene linked to prostate issues.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.